Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders. In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail

[Translation]

September 14, 2022

To: Shareholders

Company Name: Renascience Inc

Name of Representative: Koji Naito, President & CEO

(Code: 4889 TSE Growth)

Inquiries: Hiroyasu Ishimaru, Corporate Officer in Charge of Administration and Corporate Planning

Notification of the Filing of a New Medical Device Registration for a Disposable Ultrafine Endoscope

A novel seed of a medical device, "Disposable Ultrafine Endoscope for Non-Invasive Peritoneal Observation during Peritoneal Dialysis (*1)", which the Company (a spin-out biotech from Tohoku University) has developed in collaboration with Tohoku University, Juntendo University, St. Luke's International University, and other universities, with the support of the Japan Agency for Medical Research and Development (AMED), has been filed for approval to the Pharmaceuticals and Medical Devices Agency (PMDA).

This product is an ultrafine endoscope (about 1mm in diameter) that is inserted through a tube that is implanted in the peritoneum for the purpose of injecting dialysis fluid in peritoneal dialysis patients, and allows non-invasive observation of the intra-abdominal cavity. The fiberscope (*3) , the main body of the endoscope, has been filed this time, without the guide catheter (*2), which is an accessory.

Peritoneal dialysis is a treatment for chronic renal failure that allows home care and has medical and economic advantages. Peritoneal dialysis treatment based on home care is less burdensome for patients and is an ideal treatment method, compared to hemodialysis (3 times a week, 4 hours each). However, the peritoneal membrane deteriorates over time and can cause serious complications, and therefore peritoneal dialysis is forced to discontinue after about five years. Currently, the only way to check the condition of the peritoneum is through laparotomy or observation using a abdominoscope. This product allows non-invasive observation of the peritoneal cavity through an endoscope, facilitating diagnosis of complications and further improving the quality of life of peritoneal dialysis patients.

The Company does not currently anticipate any impact on its business performance as a result of this matter.

(*1) Peritoneal dialysis: This treatment uses the peritoneum (a thin membrane covering the stomach, intestines and other organs) of the body as a dialysis apparatus. When a tube (catheter) is passed through the abdominal cavity and dialysis fluid is injected, waste products in the blood, unnecessary urinary toxins, electrolytes, and excess water move into the dialysis fluid and the blood becomes clean.

(*2) Guide catheter (disposable): The tip of the fiberscope can be manipulated easily when the guide catheter is combined with the fiberscope. However, it is possible to observe the condition of the peritoneum with the fiberscope alone without using a guide catheter, though the guide catheter improves operability of the fiberscope.

(*3) Fiberscope (disposable): The main body of a disposable ultrafine endoscope. The tip is about 1 mm in diameter and passes through a tube implanted in the abdomen.

End